The Enterprise Value as of December 2024 (TTM) for TCR2 Therapeutics Inc. (TCRR) is 79.12M

According to TCR2 Therapeutics Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 79.12M. This represents a change of 0.38% compared to the average of 78.82M of the last 4 quarters.

TCR2 Therapeutics Inc. (TCRR) Historical Enterprise Value (quarterly & annually)

How has TCRR Enterprise Value performed in the past?

The mean historical Enterprise Value of TCR2 Therapeutics Inc. over the last ten years is 210.93M. The current 79.12M Enterprise Value has changed 3.65% with respect to the historical average. Over the past ten years (40 quarters), TCRR's Enterprise Value was at its highest in in the December 2020 quarter at 940.40M. The Enterprise Value was at its lowest in in the December 2021 quarter at -17772885.30.

TCR2 Therapeutics Inc. (TCRR) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of TCR2 Therapeutics Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

TCR2 Therapeutics Inc. (TCRR) Average Enterprise Value

How has TCRR Enterprise Value performed in the past?

The current Enterprise Value of TCR2 Therapeutics Inc. (TCRR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

TCR2 Therapeutics Inc. (TCRR) Enterprise Value vs. Peers

How is TCRR’s Enterprise Value compared to its peers?

TCR2 Therapeutics Inc.’s Enterprise Value is greater than Affimed N.V. (22.90M), greater than Pieris Pharmaceuticals, Inc. (-1407736.00), less than ADC Therapeutics SA (249.65M), greater than Agenus Inc. (74.19M), less than Revolution Medicines, Inc. (7.90B), less than Black Diamond Therapeutics, Inc. (123.50M), greater than Atreca, Inc. (-8620212.00), greater than Passage Bio, Inc. (33.56M), less than Harpoon Therapeutics, Inc. (861.85M), less than Alector, Inc. (185.51M), greater than Homology Medicines, Inc. (-103303255.00), less than Stoke Therapeutics, Inc. (467.23M),

Build a custom stock screener for TCR2 Therapeutics Inc. (TCRR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TCR2 Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

TCR2 Therapeutics Inc. (TCRR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like TCR2 Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.